Blinatumomab Combination Therapy Wins Prestigious Trial of the Year Award for Pediatric Leukemia Breakthrough
The Children's Oncology Group AALL1731 trial received the David Sackett Trial of the Year Award for demonstrating that adding blinatumomab to chemotherapy reduces relapse risk by about two-thirds in children with B-cell acute lymphoblastic leukemia.
Racial and Ethnic Disparities Persist in Pediatric Neuroblastoma Survival Despite Clinical Trial Access
Black and Hispanic children with high-risk neuroblastoma experience significantly worse survival outcomes compared to white peers, even when treated in standardized clinical trials, according to new research from UT Southwestern Medical Center.
Blinatumomab Plus Chemotherapy Significantly Improves Survival in Pediatric ALL
A clinical trial demonstrated that adding blinatumomab to chemotherapy significantly improves three-year disease-free survival (DFS) rates in children with standard-risk acute lymphoblastic leukemia (ALL).
Larotrectinib Shows High Efficacy in Pediatric Solid Tumors with NTRK Fusion
Larotrectinib demonstrates high effectiveness in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) and other solid tumors harboring NTRK gene fusions.
Novel Agents Identified for Osteosarcoma Treatment in Children and Young Adults
The Children's Oncology Group has prioritized several novel agents for osteosarcoma treatment, addressing the lack of progress in outcomes for decades.
Lorlatinib Shows Promise in ALK-Driven Refractory Neuroblastoma with Emerging Resistance Mechanisms Identified
A phase 1 trial of lorlatinib in ALK-driven refractory neuroblastoma demonstrated safety and efficacy across all common ALK mutations, with a recommended pediatric dose of 115 mg/m² daily - approximately twice the adult dose.